Winette van der Graaf, MD, PhD

Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center
Amsterdam, Zuid-Holland, Netherlands

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 103 - NIROGACESTAT TREATMENT IN ADULT PATIENTS WITH DESMOID TUMORS: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 3 DEFI TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST